African Trypanosomiasis - Pipeline Review, H2 2017

Publication ID:
GMD0817070

Publication Date:
August 22, 2017

Pages:
47

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *

- Single User License (PDF), $2,000.00
- Site License (PDF), $4,000.00
- Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
African Trypanosomiasis - Pipeline Review, H2 2017

Summary


African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 3 molecules, respectively.

African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of African
Trypanosomiasis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
African Trypanosomiasis - Overview
African Trypanosomiasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
African Trypanosomiasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
African Trypanosomiasis - Companies Involved in Therapeutics Development
Merck & Co Inc
Novartis AG
Sanofi
Scynexis Inc
African Trypanosomiasis - Drug Profiles
AN-5568 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBL-0137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-100097 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNF-6702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melarsoprol hydroxypropylbetadex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Sleeping Sickness - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Sleeping Sickness - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
African Trypanosomiasis - Dormant Projects
African Trypanosomiasis - Discontinued Products
African Trypanosomiasis - Product Development Milestones
Featured News & Press Releases
Aug 30, 2016: UGA researchers discover a drug for a tropical disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development for African Trypanosomiasis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
African Trypanosomiasis - Pipeline by Merck & Co Inc, H2 2017
African Trypanosomiasis - Pipeline by Novartis AG, H2 2017
African Trypanosomiasis - Pipeline by Sanofi, H2 2017
African Trypanosomiasis - Pipeline by Scynexis Inc, H2 2017
African Trypanosomiasis - Dormant Projects, H2 2017
African Trypanosomiasis - Discontinued Products, H2 2017

List of Figures
List of Figures
Number of Products under Development for African Trypanosomiasis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Companies Mentioned:
Merck & Co Inc
Novartis AG
Sanofi
Scynexis Inc

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate
location by an organization that wishes to use the publication within the same organization.

- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.